Neurogene Inc. NGNE 深 沪
等待开盘 08-13 09:30:00 美东时间
36.98
+1.180
+3.30%
华盛通- 最 高37.275
- 今 开36.59
- 成交量 34.26万股
- 最 低 35.715
- 昨 收 35.80
- 总市值 7.14亿
- 52周最高 43.66
- 市盈率 静 --
- 换手率 1.78%
- 52周最低 15.93
- 委 比 -59.84%
- 总股本 1930.19万
- 历史最高 362.60
- 量 比 1.84
- 振 幅 4.36%
- 历史最低 6.875
- 每 手 1
- 风险率 6.31%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | 业绩大超预期！ CoreWeave、超微电脑、Lumentum绩后获多家大行上调目标价
今日重点评级关注：Canaccord Genuity：维持Sagimet Biosciences"买入"评级，目标价从49美元升至56美元；韦德布什：维持Zura Bio"跑赢大市"评级，目标价从15美元升至22美元
今天 11:44
HC Wainwright & Co. Maintains Buy on Neurogene, Lowers Price Target to $65
HC Wainwright & Co. analyst Mitchell S. Kapoor maintains Neurogene (NASDAQ:NGNE) with a Buy and lowers the price target from $70 to $65.
08-12 19:40
Neurogene Q2 EPS $(1.53) Misses $(1.39) Estimate
Neurogene (NASDAQ:NGNE) reported quarterly losses of $(1.53) per share which missed the analyst consensus estimate of $(1.39) by 10.07 percent. This is a 45.71 percent decrease over losses of $(1.05) per share from the same period last year.
08-11 19:45
美股牛股 | 制药企业CRNX股价狂飙近99%！获福泰制药百亿美元高溢价收购；罕见病药物研究公司AGIO涨18%
制药企业CRNX股价狂飙近99%！获福泰制药百亿美元高溢价收购；罕见病药物研究公司AGIO涨18%，核心产品新药申请获FDA受理；基因治疗药物研发企业NGNE涨13%，公司成功完成新一轮融资>>
07-08 19:19
Neurogene bolsters cash runway with equity offering
An update from Neurogene ( ($NGNE) ) is now available. On June 30, 2026, Neurog...
07-02 18:28
Neurogene prices $125M equity offering
Neurogene (NGNE) priced a public offering of 3.5M common shares at $30.00 per share and 666,666 pre-funded warrants in lieu of common stock for certain investors. The pre-funded warrants are exercisab...
07-01 19:19
Neurogene Prices $125M Public Offering At $30/Share, $29.999999 Pre‑Funded Warrants
Neurogene Inc. (NASDAQ:NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced the pricing of its previously announced public offering of 3,500,000 shares of its common stock at a public offerin...
07-01 19:04
Neurogene Reveals Proposed Public Offering; No Size Disclosed
Neurogene Inc. (NASDAQ:NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced that it has commenced a public offering of shares of its common stock or, in lieu of common stock to certain invest...
07-01 04:02
Neurogene Announces Updated Data From Phase 1/2 Clinical Trial Evaluating NGN-401 Gene Therapy For Treatment Of Females With Rett Syndrome
47 total developmental milestones gained across 10 participants, with durable treatment effect and no plateau or milestone loss through 30 months of follow-up 100% of participants improved in CGI-I score and gained ≥1 developmental milestone, with an average of 4.7 milestones per participant, and al...
06-29 19:17
